Nippon Shinyaku Co Ltd   Report issue

For profit Phase 1 Phase 2 Phase 4
Founded: Kyoto Japan (1911)

Organization Overview

First Clinical Trial
2002
NCT00094003
First Marketed Drug
2020
viltolarsen (Viltepso)
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Funded by Toyo Shinyaku Co Ltd | NIPPON SHINYAKU | Nippon Shinyaku Co., Ltd. | NS Pharma, Inc. | Toyo Shinyaku Co Ltd